Skip to content
New: 30 more Indian companies explained, from Ather and Pine Labs to IDBI Bank

Compare · Healthcare

Cipla vs Dr. Reddy's: how their businesses differ

The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

How they differ

In FY26, Dr. Reddy's revenue of ₹33,700 cr was about 1.2 times Cipla's ₹28,163 cr (Cityfort calculation: one divided by the other).

Cipla's largest segment is One India, 45.0% of revenue in FY26; Dr. Reddy's largest segment is Global Generics, 88.9% of revenue in FY26.

India brought in 45.0% of Cipla's revenue in FY26; India brought in 19.2% of Dr. Reddy's revenue in FY26.

Cipla's largest payer group is Customers in India, 45.0% of revenue (FY26); Dr. Reddy's largest payer group is Buyers of finished medicines, 88.9% of revenue (FY26).

Neither page lists the other among its competitors.

Sources: Cipla S15, S1, S16, S31 · Dr. Reddy's S11, S1, S12, S2

Each company in 5 points

Cipla

  1. 1 · What it sells

    Cipla makes branded and generic medicines, including inhalers for breathing conditions, and its FY26 revenue from operations was ₹28,163 crore.

    Sources and detail on the Cipla page
  2. 2 · Who pays it

    In FY26, customers in India paid 45.0% of Cipla's revenue, the US 24.4%, Africa 15.2% and the rest of the world 15.4%.

    Sources and detail on the Cipla page
  3. 3 · What it keeps from ₹100

    Of every ₹100 that came in during FY26, Cipla kept ₹13.4 as profit, after a ₹276 crore one-off labour-code charge and including ₹882 crore of other income, while its EBITDA before the one-off charge was 20.9% of revenue (Cityfort calculation).

    Sources and detail on the Cipla page
  4. 4 · Where the operating profit comes from

    Cipla has reported a single segment since FY26, so it does not disclose which business earns its FY26 EBITDA of ₹5,883 crore before the one-off charge (Cityfort calculation); India gave 45.0% of revenue.

    Sources and detail on the Cipla page
  5. 5 · The one thing to watch

    North America sales fell from US$233 million in Q2 FY26 to US$172 million in Q2 FY27, and management said on 27 Oct 2026 it keeps its aim of a US$1 billion run rate towards the end of FY27.

    Sources and detail on the Cipla page

Dr. Reddy's

  1. 1 · What it sells

    The company makes generic and branded medicines and the active ingredients that go into them, and its FY26 revenue from operations was ₹33,700 crore.

    Sources and detail on the Dr. Reddy's page
  2. 2 · Who pays it

    In FY26, customers in the US paid 35.1% of the company's revenue, customers in India 19.2%, Russia 10.4% and all other countries 35.3%.

    Sources and detail on the Dr. Reddy's page
  3. 3 · What it keeps from ₹100

    Of every ₹100 that came in during FY26, including ₹1,358 crore of other income, the company kept ₹12.0 as profit for shareholders, and its operating EBITDA margin on revenue was 19.1% (Cityfort calculation, after ₹352 crore of write-downs).

    Sources and detail on the Dr. Reddy's page
  4. 4 · Where the operating profit comes from

    Global Generics earned ₹16,970 crore of the company's ₹17,728 crore FY26 gross profit, while active ingredients and services (PSAI) earned ₹600 crore.

    Sources and detail on the Dr. Reddy's page
  5. 5 · The one thing to watch

    US lenalidomide exclusivity ended in Jan 2026, and the company's North America revenue was ₹2,489 crore in Q2 FY27, 23% lower than a year earlier by its own count.

    Sources and detail on the Dr. Reddy's page

Where each ₹100 went

Each company's own receipt for its latest full financial year, with matching lines in the same order where both have them.

Cipla

Where ₹100 went · FY26

Where ₹100 of Cipla's money went in FY26
Materials and goods bought₹32.9
Employee costs₹18.5
Other running costs₹25.4
Depreciation and interest₹4.4
One-off labour-code charge₹0.9
Income tax₹4.7
Kept as profit for shareholders₹13.4
Total₹100

Cityfort calculation from the FY26 annual report: each line ÷ total money in (revenue of ₹28,163 crore plus ₹882 crore of other income) × 100. Profit is the shareholders' share: ₹9 crore more than money in minus the costs shown, because minority partners took ₹17 crore of losses and part-owned companies lost ₹8 crore.

Dr. Reddy's

Where ₹100 went · FY26

Where ₹100 of Dr. Reddy's's money went in FY26
Materials and goods bought₹34.9
Employees₹17.1
Other running costs (incl. write-downs)₹25.7
Depreciation and amortisation₹5.9
Interest₹1.1
Income tax₹3.5
Kept as profit for shareholders₹12.0
Total₹100

Cityfort calculation from the FY26 audited results: each line ÷ ₹35,110 crore that came in (revenue ₹33,700 crore, other income ₹1,358 crore, and ₹52 crore from associates and minority partners' share of losses). Other running costs include ₹352 crore of write-downs. ₹12.0 was kept as profit; rounded lines add to 100.2.

Line items differ because each company groups its costs its own way in its filings. Only on Cipla's receipt: Employee costs; Other running costs; Depreciation and interest; One-off labour-code charge. Only on Dr. Reddy's receipt: Employees; Other running costs (incl. write-downs); Depreciation and amortisation; Interest.

Sources: Cipla S15, S1, S16 · Dr. Reddy's S11, S1, S12

Revenue, net profit and free cash flow

Up to five financial years for each company, drawn on one shared scale per measure. Amounts in ₹ crore as each company reports them.

Revenue

Cipla

Dr. Reddy's

Both charts use the same scale. Indian financial years (April to March).
See the numbers
Revenue of Cipla and Dr. Reddy's by financial year, ₹ crore
Cipla yearCipla revenueDr. Reddy's yearDr. Reddy's revenue
FY22₹21,763 crFY22₹21,545 cr
FY23₹22,753 crFY23₹24,670 cr
FY24₹25,774 crFY24₹28,011 cr
FY25₹27,548 crFY25₹32,644 cr
FY26₹28,163 crFY26₹33,700 cr

Net profit

Cipla

Dr. Reddy's

Both charts use the same scale. Indian financial years (April to March).
See the numbers
Net profit of Cipla and Dr. Reddy's by financial year, ₹ crore
Cipla yearCipla net profitDr. Reddy's yearDr. Reddy's net profit
FY22₹2,517 crFY22₹2,183 cr
FY23₹2,802 crFY23₹4,507 cr
FY24₹4,122 crFY24₹5,578 cr
FY25₹5,273 crFY25₹5,655 cr
FY26₹3,879 crFY26₹4,196 cr

Free cash flow

Cipla

Dr. Reddy's

Both charts use the same scale. Indian financial years (April to March); free cash flow = cash from operations minus capital spending, as on each company's page.
See the numbers
Free cash flow of Cipla and Dr. Reddy's by financial year, ₹ crore
Cipla yearCipla free cash flowDr. Reddy's yearDr. Reddy's free cash flow
FY22₹2,625 crFY22₹906 cr
FY23₹2,055 crFY23₹4,001 cr
FY24₹2,785 crFY24₹1,800 cr
FY25₹3,457 crFY25₹1,203 cr
FY26₹861 crFY26₹1,833 cr

Sources: Cipla S34, S5, S4, S33, S32, S3, S26, S2, S15, S1, S16 · Dr. Reddy's S25, S24, S23, S22, S20, S19, S1, S11, S12

Growth and net margin, FY22 to FY26

Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net profit as a share of revenue, as on each page.

Cipla

Revenue, per year
+6.7%
Net profit, per year
+11.4%

Dr. Reddy's

Revenue, per year
+11.8%
Net profit, per year
+17.7%

Cityfort calculation: compound growth per year from FY22 to FY26 (4 years), from each page's yearly numbers, as reported.

Net margin by year
Net margin (net profit as a share of revenue) of Cipla and Dr. Reddy's by financial year, as on each page
YearCiplaDr. Reddy's
FY2211.6%10.1%
FY2312.3%18.3%
FY2416.0%19.9%
FY2519.1%17.3%
FY2613.8%12.5%

Sources: Cipla S34, S5, S4, S33, S32, S3, S26, S2, S15, S1, S16 · Dr. Reddy's S25, S24, S23, S22, S20, S19, S1, S11, S12

Latest quarter, against the same quarter a year earlier

Each page's latest quarter as reported; the change is a Cityfort calculation.

Cipla

Q2 FY27, the quarter to 30 Sep 2026, against Q2 FY26

Cipla, Q2 FY27 against Q2 FY26
MeasureQ2 FY27Q2 FY26Change
Revenue₹7,404 cr₹7,589 cr−2.4%
Net profit₹878 cr₹1,351 cr−35.0%

Dr. Reddy's

Q2 FY27, the quarter to 30 Sep 2026, against Q2 FY26

Dr. Reddy's, Q2 FY27 against Q2 FY26
MeasureQ2 FY27Q2 FY26Change
Revenue₹8,698 cr₹8,828 cr−1.5%
Net profit₹925 cr₹1,347 cr−31.3%

Sources: Cipla S22, S18, S19, S15, S11, S6, S8 · Dr. Reddy's S17, S14, S11, S12, S7, S8, S3, S4

Who pays each company

Cipla

  • Customers in India · 45.0% of revenueDistributors and retailers that sell Cipla's prescription brands, trade generics and consumer products to patients. Share is of FY26 revenue by customer location.
  • Customers in the US · 24.4% of revenueBuyers of Cipla's generic medicines in the US: ₹6,872 crore of revenue in FY26, down from ₹7,899 crore in FY25.
  • Customers in Africa · 15.2% of revenuePrivate-market buyers in South Africa and other African countries, and governments and global health programmes buying through tenders.
  • Customers in the rest of the world · 15.4% of revenueBuyers in other emerging markets and Europe, and companies buying drug ingredients.

Dr. Reddy's

  • Buyers of finished medicines · 88.9% of revenueWholesalers, distributors, pharmacy chains, hospitals and government institutions buying the Global Generics segment's medicines. Share is of FY26 revenue.
  • Other drug makers · 10.5% of revenueBuy active ingredients and contract research and manufacturing services (PSAI segment). Share is after removing PSAI's sales to Dr. Reddy's own generics business.
  • Others · 0.6% of revenueAurigene Oncology (a drug discovery business) and proprietary products.

Sources: Cipla S1, S16 · Dr. Reddy's S1, S2

Revenue by segment

Cipla

FY26

Cipla revenue by segment, FY26
SegmentRevenueShare
One India₹12,680 cr45.0%
North America₹6,871 cr24.4%
One Africa₹4,287 cr15.2%
Emerging markets and Europe₹3,576 cr12.7%
API and others₹749 cr2.7%

Dr. Reddy's

FY26

Dr. Reddy's revenue by segment, FY26
SegmentRevenueShare
Global Generics₹29,946 cr88.9%
Pharmaceutical Services and Active Ingredients (PSAI)₹3,540 cr10.5%
Others₹214 cr0.6%

Sources: Cipla S16, S31 · Dr. Reddy's S1

Where the revenue comes from

Revenue by region, as each company splits it, with the period.

Cipla

FY26

  • India45.0%
  • United States24.4%
  • Africa15.2%
  • Rest of the world15.4%

Dr. Reddy's

FY26

  • United States35.1%
  • India19.2%
  • Russia10.4%
  • Other countries35.3%

Sources: Cipla S1 · Dr. Reddy's S1

Borrowings and cash

Cipla

Borrowings
₹267 cr
Cash and investments
₹8,238 cr

On 30 Sep 2026.

On 30 Sep 2026 Cipla's cash and liquid investments were ₹7,971 crore more than its borrowings of ₹267 crore (Cityfort calculation from the Q2 FY27 results).

Dr. Reddy's

Borrowings
₹5,826 cr
Cash and investments
₹6,874 cr

On 30 Sep 2026.

On 30 Sep 2026 Dr. Reddy's cash and short-term investments were ₹1,048 crore more than its borrowings (Cityfort calculation from the Q2 FY27 results).

Sources: Cipla S6, S7, S8 · Dr. Reddy's S3, S5, S6, S19, S22, S38

Who owns each company

Cipla

  • Promoters: 29.2%
  • Foreign institutional investors (FIIs): 20.3%
  • Indian institutions (DIIs): 34.9%
  • Public: 15.6%
  • Pledged: 0.0% of the promoter holding.
  • Shareholding pattern at the end of Q2 FY27.

Dr. Reddy's

  • Promoters: 26.6%
  • Foreign institutional investors (FIIs): 20.3%
  • Indian institutions (DIIs): 31.9%
  • Public: 9.9%
  • Shares behind US-listed ADRs (held by JP Morgan Chase Bank as depository; filed inside foreign institutions): 11.1%
  • Pledged: 0.0% of the promoter holding.
  • Shareholding pattern at the end of Q2 FY27.

Sources: Cipla S35, S36, S37, S38, S39, S40, S41, S42, S43, S44, S45, S46 · Dr. Reddy's S26, S27, S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S42

What protects each business

What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.

Cipla

  • Respiratory medicines in India

    CARE's Aug 2025 report put Cipla's share of India's respiratory medicine market at 25.3%, with Cipla second in urology and chronic medicines.

  • US inhalers

    Cipla's albuterol had 22% of the US albuterol inhaler market (IQVIA, week to 25 Sep 2026). Generic Ventolin launched in Q1 FY27 and generic Advair was approved on 27 Jul 2026.

  • Size in India

    ₹14,839 crore of India medicine sales and a 5.8% share in the 12 months to Jun 2026 (AIOCD), against 8.5% for Sun Pharma.

  • Africa

    Cipla says it is second in South Africa's prescription market (IQVIA, Aug 2026). One Africa sold ₹4,287 crore in FY26, up 12%.

  • Cash on hand

    On 30 Sep 2026 cash and liquid investments of ₹8,238 crore against borrowings of ₹267 crore. CARE rated Cipla AAA (Stable) on 26 Aug 2025.

Dr. Reddy's

  • Own ingredient supply

    The PSAI segment makes active ingredients and sold ₹727 crore of them to Dr. Reddy's own generics business in FY26. ICRA (Jan 2026) says this backward integration gives a significant cost advantage.

  • Spread across markets

    In FY26 customers in the US paid 35.1% of revenue, India 19.2%, Russia 10.4% and other countries 35.3%. It sold in 87 countries.

  • US filings pipeline

    77 generic and 3 new-drug applications were pending with the US FDA in Sep 2026, including 27 first-to-file.

  • India brands

    The company says, citing IQVIA, it ranked 8th in India in the quarter to Sep 2026, and its India sales grew 21.0% against the market's 14.7%.

  • Cash and borrowings

    On 30 Sep 2026 cash and short-term investments exceeded borrowings by ₹1,048 crore (Cityfort calculation). ICRA rated it AA+/Stable on 9 Jan 2026.

Sources: Cipla S47, S8, S87, S88, S14, S92, S16, S6, S7 · Dr. Reddy's S1, S38, S2, S5, S3, S72

Where growth could come from

Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.

Cipla

  • Medicines in India · Working: on track against what the company said₹3,516 crore, Q2 FY27 (+12%)
  • North America · Behind: behind the company's own planUS$172 million, Q2 FY27 (US$233 million a year earlier)
  • New US inhalers · Early: too early to judgeGeneric Ventolin launched Q1 FY27; generic Advair approved 27 Jul 2026
  • Yurpeak (tirzepatide) in India · Early: too early to judgeLaunched 10 Dec 2025
  • Africa · Mixed: partly on track₹1,171 crore, Q2 FY27 (−1%)
  • Biosimilars and licensed medicines · New: recently announced60:40 biologics joint venture with Kemwell (Mar 2026)

Dr. Reddy's

  • Semaglutide (diabetes and weight-loss injection) · Behind: behind the company's own plan₹239.7 crore provision, Q1 FY27
  • India · Working: on track against what the company said+17% YoY, Q2 FY27 (company figure)
  • Emerging markets · Working: on track against what the company said+24% YoY, Q2 FY27 (company figure)
  • North America without lenalidomide · Mixed: partly on track₹2,489 crore, −23% YoY, Q2 FY27
  • Europe and nicotine gums · Mixed: partly on track+1% YoY, Q2 FY27 (company figure)
  • Abatacept biosimilar · Early: too early to judgeUS approval awaited

Sources: Cipla S8, S85, S86, S19, S23, S21, S78, S87, S88, S14, S10, S16, S90, S9 · Dr. Reddy's S64, S67, S41, S8, S70, S5, S12, S38, S6, S48

Dividends, buybacks, auditor and credit rating

Dividends per share and buybacks for up to five years, the statutory auditor and the latest credit rating, as each page records them.

Cipla

  • Dividends per shareFY22: ₹5.00 (16.0% of profit) · FY23: ₹8.50 (24.5% of profit) · FY24: ₹13.00 (25.5% of profit) · FY25: ₹16.00 (24.5% of profit) · FY26: ₹13.00 (27.1% of profit)
  • BuybacksNone on the page in the last five years.
  • AuditorB S R & Co. LLP, since 2026
  • Credit ratingCARE Ratings: CARE AAA (long term), CARE A1+ (short term), bank facilities of ₹2,268 crore, outlook Stable (26 Aug 2025)

Dr. Reddy's

  • Dividends per shareFY22: ₹6.00 (22.8% of profit) · FY23: ₹8.00 (14.7% of profit) · FY24: ₹8.00 (11.9% of profit) · FY25: ₹8.00 (11.8% of profit) · FY26: ₹8.00 (15.9% of profit)
  • BuybacksNone on the page in the last five years.
  • AuditorDeloitte Haskins & Sells LLP, since 2026
  • Credit ratingICRA: [ICRA]AA+ (long-term bank limits, ₹2,000 crore), outlook Stable (9 Jan 2026)

Sources: Cipla S5, S34, S4, S33, S3, S32, S2, S26, S1, S15, S83, S7, S47 · Dr. Reddy's S1, S25, S24, S22, S19, S12, S11, S46, S38

Risks only one page tracks

Risks whose type the other company's page does not list. Both pages track risks of these types: regulation, legal cases, execution. Every risk is on each company's page.

Cipla

  • A few US products and partners (customer or supplier concentration)North America sales fell 13% in FY26 after generic Revlimid billing ended and supply of lanreotide, made by partner Pharmathen, was paused and later recalled. Achin Gupta said on 27 Oct 2026 that the US$1 billion run-rate aim does not include lanreotide.
  • Price controls and competition (pricing)Cipla's FY26 annual report says "Government price controls, competitor and customer pressures collectively erode profitability", and names more competition in chronic medicines, particularly cardiometabolic (heart and blood-sugar) and anti-obesity medicines.

Dr. Reddy's

  • Price competition in US generics (competition)US customers paid 35.1% of FY26 revenue, down from 45.9% in FY25. After lenalidomide exclusivity ended in Jan 2026, North America revenue fell 23% in Q2 FY27 (company figure). ICRA lists US generics price competition as a challenge.
  • Weaker cash flow in H1 FY27 (liquidity)Operating cash flow was ₹435 crore in H1 FY27, against ₹3,020 crore in H1 FY26. After ₹802 crore of capex, free cash flow was −₹367 crore.

Sources: Cipla S16, S21, S78, S80, S8, S10, S1 · Dr. Reddy's S1, S5, S38, S3, S17, S6

Key facts

How does Cipla make money compared with Dr. Reddy's?
Cipla's revenue by segment in FY26: One India 45.0%, North America 24.4%, One Africa 15.2%, Emerging markets and Europe 12.7%, API and others 2.7%. Dr. Reddy's revenue by segment in FY26: Global Generics 88.9%, Pharmaceutical Services and Active Ingredients (PSAI) 10.5%, Others 0.6%.
Which is bigger by revenue, Cipla or Dr. Reddy's?
Cipla reported revenue of ₹28,163 cr in FY26, and Dr. Reddy's reported revenue of ₹33,700 cr in FY26.
How much net profit did Cipla and Dr. Reddy's report?
Cipla reported a net profit of ₹3,879 cr in FY26, and Dr. Reddy's reported ₹4,196 cr in FY26.
How much of every ₹100 did Cipla and Dr. Reddy's keep as profit?
Cipla kept ₹13.4 of every ₹100 that came in during FY26, and Dr. Reddy's kept ₹12.0 in FY26 (Cityfort calculation from each company's annual report).
How much do Cipla and Dr. Reddy's owe, and how much cash do they hold?
Cipla had borrowings of ₹267 cr and cash and investments of ₹8,238 cr on 30 Sep 2026. Dr. Reddy's had borrowings of ₹5,826 cr and cash and investments of ₹6,874 cr on 30 Sep 2026.
Who owns Cipla and Dr. Reddy's?
Promoters held 29.2% of Cipla's shares at the end of Q2 FY27, with none of it pledged. Promoters held 26.6% of Dr. Reddy's shares at the end of Q2 FY27, with none of it pledged. Both come from the shareholding patterns the companies filed with NSE and BSE.
When do Cipla's and Dr. Reddy's financial years end?
Cipla and Dr. Reddy's both use the Indian financial year, April to March. The latest full year is FY26 on the Cipla page and FY26 on the Dr. Reddy's page.

Sources: Cipla S34, S5, S4, S33, S32, S3, S26, S2, S15, S1, S16, S31, S6, S7, S8 · Dr. Reddy's S25, S24, S23, S22, S20, S19, S1, S11, S12, S2, S3, S5, S6, S38

Built from each company's page. Cipla updated 11 Nov 2026; Dr. Reddy's updated 17 Nov 2026.

Sources

Cipla

  1. S1Integrated Annual Report 2025-26 (FY26), Cipla Ltd (filed with NSE), 1 Jun 2026
  2. S2Integrated Annual Report 2024-25 (FY25), Cipla Ltd (filed with NSE), 19 Jun 2025
  3. S3Annual Report 2023-24 (FY24), Cipla Ltd (filed with NSE), 26 Jul 2024
  4. S4Annual Report 2022-23 (FY23; NSE zip), Cipla Ltd (filed with NSE), 18 Jul 2023
  5. S5Annual Report 2021-22 (FY22; NSE zip), Cipla Ltd (filed with NSE), 5 Sep 2022
  6. S6Q2 FY27 consolidated results, Integrated Filing (Financials) XBRL, Cipla Ltd (filed with NSE), 27 Oct 2026
  7. S7Unaudited financial results Q2 FY27 (quarter and half year ended 30 Sep 2026), Cipla Ltd (filed with NSE), 27 Oct 2026
  8. S8Press release: Q2 FY27 financial results, Cipla Ltd (filed with NSE), 27 Oct 2026
  9. S9Investor presentation Q2 FY27, Cipla Ltd (filed with NSE), 27 Oct 2026
  10. S10Q2 FY27 earnings call transcript (call 27 Oct 2026), Cipla Ltd (filed with NSE), 30 Oct 2026
  11. S11Q1 FY27 consolidated results, Integrated Filing (Financials) XBRL, Cipla Ltd (filed with NSE), 23 Jul 2026
  12. S14Q1 FY27 earnings call transcript (call 23 Jul 2026), Cipla Ltd (filed with NSE), 27 Jul 2026
  13. S15Q4 FY26 / FY26 consolidated results, Integrated Filing (Financials) XBRL, Cipla Ltd (filed with NSE), 13 May 2026
  14. S16Press release: Q4 FY26 and FY26 results, Cipla Ltd (filed with NSE), 13 May 2026
  15. S18Q3 FY26 consolidated results, Integrated Filing (Financials) XBRL, Cipla Ltd (filed with NSE), 23 Jan 2026
  16. S19Unaudited financial results Q3 FY26 (quarter ended 31 Dec 2025; scanned), Cipla Ltd (filed with NSE), 23 Jan 2026
  17. S21Q3 FY26 earnings call transcript (call 23 Jan 2026), Cipla Ltd (filed with NSE), 27 Jan 2026
  18. S22Q2 FY26 consolidated results, Integrated Filing (Financials) XBRL, Cipla Ltd (filed with NSE), 30 Oct 2025
  19. S23Press release: Q2 FY26 results, Cipla Ltd (filed with NSE), 30 Oct 2025
  20. S26Q4 FY25 / FY25 consolidated results, Integrated Filing (Financials) XBRL, Cipla Ltd (filed with NSE), 13 May 2025
  21. S31Press release: Q4 FY24 and FY24 results, Cipla Ltd (filed with NSE), 10 May 2024
  22. S32Q4 FY24 / FY24 consolidated results XBRL, Cipla Ltd (filed with NSE), 11 May 2024
  23. S33Q4 FY23 / FY23 consolidated results XBRL, Cipla Ltd (filed with NSE), 12 May 2023
  24. S34Q4 FY22 / FY22 consolidated results XBRL, Cipla Ltd (filed with NSE), 11 May 2022
  25. S35Shareholding pattern as of 31 Dec 2023 (NSE XBRL), NSE (company filing), 19 Jan 2024
  26. S36Shareholding pattern as of 31 Mar 2024 (NSE XBRL), NSE (company filing), 19 Apr 2024
  27. S37Shareholding pattern as of 30 Jun 2024 (NSE XBRL), NSE (company filing), 20 Jul 2024
  28. S38Shareholding pattern as of 30 Sep 2024 (NSE XBRL), NSE (company filing), 21 Oct 2024
  29. S39Shareholding pattern as of 31 Dec 2024 (NSE XBRL), NSE (company filing), 20 Jan 2025
  30. S40Shareholding pattern as of 31 Mar 2025 (NSE XBRL), NSE (company filing), 21 Apr 2025
  31. S41Shareholding pattern as of 30 Jun 2025 (re-filed 21 Oct 2025) (NSE XBRL), NSE (company filing), 21 Oct 2025
  32. S42Shareholding pattern as of 30 Sep 2025 (NSE XBRL), NSE (company filing), 21 Oct 2025
  33. S43Shareholding pattern as of 31 Dec 2025 (NSE XBRL), NSE (company filing), 21 Jan 2026
  34. S44Shareholding pattern as of 31 Mar 2026 (revised filing 11 Aug 2026; original 21 Apr 2026) (NSE XBRL), NSE (company filing), 11 Aug 2026
  35. S45Shareholding pattern as of 30 Jun 2026 (NSE XBRL), NSE (company filing), 21 Jul 2026
  36. S46Shareholding pattern as of 30 Sep 2026 (NSE XBRL), NSE (company filing), 21 Oct 2026
  37. S47CARE Ratings press release: Cipla Limited, bank facilities reaffirmed CARE AAA; Stable / CARE A1+, CARE Ratings Limited, 26 Aug 2025
  38. S78Update on lanreotide supply after USFDA observations at Pharmathen, Cipla Ltd (filing to NSE/BSE), 14 Jan 2026
  39. S80Cipla USA to recall unexpired lanreotide batches, Cipla Ltd (filing to NSE/BSE), 9 Mar 2026
  40. S8390th AGM approves B S R & Co. LLP; Walker Chandiok & Co LLP completes second term, Cipla Ltd (filing to NSE/BSE), 25 Jun 2026
  41. S85Launch of Yurpeak (tirzepatide) in India under distribution agreement with Eli Lilly, Cipla Ltd (filing to NSE/BSE), 10 Dec 2025
  42. S86Exclusive 5-year supply and marketing agreement for four Pfizer brands in India, Cipla Ltd (filing to NSE/BSE), 19 Dec 2025
  43. S87USFDA approval for first AB-rated generic of Ventolin HFA (albuterol), Cipla Ltd (filing to NSE/BSE), 23 Apr 2026
  44. S88USFDA approval for generic Advair Diskus, Cipla Ltd (filing to NSE/BSE), 27 Jul 2026
  45. S9060:40 biologics joint venture agreement with Kemwell Biopharma, Cipla Ltd (filing to NSE/BSE), 2 Mar 2026
  46. S92Sun Pharmaceutical Industries: investor presentation, September 2026 (India formulation market share chart, AIOCD AWACS MAT Jun 2026), Sun Pharmaceutical Industries Ltd (company IR site), 22 Sep 2026

Dr. Reddy's

  1. S1Integrated Annual Report FY2025-26, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 30 Jun 2026
  2. S2Business Responsibility and Sustainability Report FY2025-26, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 30 Jun 2026
  3. S3Q2 FY27 consolidated financial results (Ind AS, NSE XBRL), NSE (company filing), 23 Oct 2026
  4. S4Q2 FY27 results filing: board outcome and financial results (PDF), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 23 Oct 2026
  5. S5Q2 FY27 results presentation (IFRS), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 23 Oct 2026
  6. S6Q2 FY27 earnings call transcript (23 Oct 2026), Dr. Reddy's Laboratories Ltd (company website; filed with NSE/BSE 29 Oct 2026), 29 Oct 2026
  7. S7Q1 FY27 consolidated financial results (Ind AS, NSE XBRL), NSE (company filing), 22 Jul 2026
  8. S8Q1 FY27 results filing (PDF, notes), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 22 Jul 2026
  9. S11Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 12 May 2026
  10. S12Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 12 May 2026
  11. S14Q3 FY26 consolidated financial results (Ind AS, NSE XBRL), NSE (company filing), 21 Jan 2026
  12. S17Q2 FY26 consolidated financial results (Ind AS, NSE XBRL), NSE (company filing), 24 Oct 2025
  13. S19Q4 FY25 and FY25 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 9 May 2025
  14. S20Q4 FY25 results filing (PDF; FY24 comparatives and split-adjusted EPS), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 9 May 2025
  15. S22Q4 FY24 and FY24 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 7 May 2024
  16. S23Q4 FY24 results filing (PDF; FY23 comparatives), Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 7 May 2024
  17. S24Q4 FY23 and FY23 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 10 May 2023
  18. S25Q4 FY22 and FY22 audited consolidated results (Ind AS, NSE XBRL), NSE (company filing), 19 May 2022
  19. S26Shareholding pattern as of Dec 2023 (NSE XBRL), NSE (company filing), 19 Jan 2024
  20. S27Shareholding pattern as of Mar 2024 (NSE XBRL), NSE (company filing), 19 Apr 2024
  21. S28Shareholding pattern as of Jun 2024 (revised filing) (NSE XBRL), NSE (company filing), 19 Jul 2024
  22. S29Shareholding pattern as of Sep 2024 (NSE XBRL), NSE (company filing), 21 Oct 2024
  23. S30Shareholding pattern as of Dec 2024 (NSE XBRL), NSE (company filing), 21 Jan 2025
  24. S31Shareholding pattern as of Mar 2025 (NSE XBRL), NSE (company filing), 19 Apr 2025
  25. S32Shareholding pattern as of Jun 2025 (NSE XBRL), NSE (company filing), 21 Jul 2025
  26. S33Shareholding pattern as of Sep 2025 (NSE XBRL), NSE (company filing), 16 Oct 2025
  27. S34Shareholding pattern as of Dec 2025 (NSE XBRL), NSE (company filing), 20 Jan 2026
  28. S35Shareholding pattern as of Mar 2026 (revised filing) (NSE XBRL), NSE (company filing), 21 Jul 2026
  29. S36Shareholding pattern as of Jun 2026 (NSE XBRL), NSE (company filing), 21 Jul 2026
  30. S37Shareholding pattern as of Sep 2026 (NSE XBRL), NSE (company filing), 21 Oct 2026
  31. S38ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable), ICRA Ltd, 9 Jan 2026
  32. S41Intimation: semaglutide batches out of specification due to API issue; supplies delayed, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 9 Jul 2026
  33. S42Disclosure: promoters transfer 20.58% to VSD Family Trust and GVP Family Trust, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 18 Sep 2025
  34. S46AGM 23 Jul 2026 outcome: Deloitte Haskins & Sells LLP appointed statutory auditors; director appointments, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 23 Jul 2026
  35. S48Intimation: US FDA pre-license inspection at biologics facility, Bachupally: Form 483 with 7 observations, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 25 Jun 2026
  36. S64Press release: launch of semaglutide injection (Obeda) in India, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 21 Mar 2026
  37. S67Press release: launch of generic semaglutide injection in Canada, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 16 May 2026
  38. S70Press release: marketing authorization for generic semaglutide injection in Brazil, Dr. Reddy's Laboratories Ltd (filing to NSE/BSE), 5 Nov 2026
  39. S72Sun Pharmaceutical Industries: investor presentation, September 2026 ("Creating Lasting Value"), India market share chart (AIOCD AWACS, MAT Jun 2026), Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE), 22 Sep 2026

Disclaimer

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.

Read the full disclaimer

Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.

All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management are reported as statements, with their date and source; they are not our forecasts.